Jul 6, 2023
David Dodd is Chairman, President, and CEO of GeoVax, which is working on vaccines that overcome restrictions of mRNA vaccines to provide longer-term, more robust protection, particularly for people who do not respond well to primary antibody stimulation. There is a strong response from T cells from this vaccine which...
Jul 6, 2023
David Dodd is Chairman, President, and CEO of GeoVax, which is working on vaccines that overcome restrictions of mRNA vaccines to provide longer-term, more robust protection, particularly for people who do not respond well to primary antibody stimulation. There is a strong response from T cells from this vaccine which...
Jun 8, 2023
Dr. Romain Micol, CEO, and Dr. Tom VanCott, Chief Scientific Officer, at Combined Therapeutics, are excited about the opportunities to design mRNA vaccines that target specific tissue cells to restrict protein expression and have stronger potency in the fight against infectious disease and cancer. They have designed...
Jun 8, 2023
Dr. Romain Micol, CEO, and Dr. Tom VanCott, Chief Scientific Officer, at Combined Therapeutics, are excited about the opportunities to design mRNA vaccines that target specific tissue cells to restrict protein expression and have stronger potency in the fight against infectious disease and cancer. They have designed...
Apr 25, 2023
Steve Reed, Co-Founder, President, and CEO of HDT Bio, has spent his life focusing on tropical diseases and points out how the cost of developing and manufacturing vaccines determines access for a global population. HDT Bio was founded to develop more cost-effective technology to induce broader immune responses to...